147 related articles for article (PubMed ID: 22673589)
1. Cutaneous T-cell lymphoma's confounding nature.
Schmidt C
J Natl Cancer Inst; 2012 Jun; 104(11):806-8. PubMed ID: 22673589
[No Abstract] [Full Text] [Related]
2. [Diagnosis and treatment for cutaneous T-cell lymphomas].
Hamada T; Iwatsuki K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():537-43. PubMed ID: 23134012
[No Abstract] [Full Text] [Related]
3. Differential expression of CCR4 in primary cutaneous gamma/delta (γ⁄δ) T cell lymphomas and mycosis fungoides: Significance for diagnosis and therapy.
Jour G; Aung PP; Merrill ED; Curry JL; Tetzlaff MT; Nagarajan P; Ivan D; Prieto VG; Duvic M; Miranda RN; Torres-Cabala CA
J Dermatol Sci; 2018 Jan; 89(1):88-91. PubMed ID: 29030090
[No Abstract] [Full Text] [Related]
4. Bexarotene and systemic disease progression in CTCL?
Dummer R; Hauschild A; Skalsky J; Burg G; Weichenthal M
J Am Acad Dermatol; 2006 Aug; 55(2):365-6; author reply 366. PubMed ID: 16844539
[No Abstract] [Full Text] [Related]
5. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
Chung CG; Poligone B
Dermatol Clin; 2015 Oct; 33(4):787-805. PubMed ID: 26433850
[TBL] [Abstract][Full Text] [Related]
6. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
7. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
8. [Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors].
Zirlik K; Nashan D; Veelken H
Pharm Unserer Zeit; 2010 May; 39(3):190-6. PubMed ID: 20425773
[No Abstract] [Full Text] [Related]
9. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
[No Abstract] [Full Text] [Related]
10. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
11. [Item no 164: malignant lymphoma: cutaneous lymphoma].
Ann Dermatol Venereol; 2005 Oct; 132(10 Suppl):7S153-7S155. PubMed ID: 16419538
[No Abstract] [Full Text] [Related]
12. Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.
Martinez-Escala ME; Posligua AL; Wickless H; Rutherford A; Sable KA; Rubio-Gonzalez B; Zhou XA; Kaplan JB; Pro B; Choi J; Querfeld C; Rosen ST; Guitart J
J Am Acad Dermatol; 2018 Jun; 78(6):1068-1076. PubMed ID: 29307643
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Willemze R; Hodak E; Zinzani PL; Specht L; Ladetto M;
Ann Oncol; 2013 Oct; 24 Suppl 6():vi149-54. PubMed ID: 23868906
[No Abstract] [Full Text] [Related]
15. Targeted therapies for cutaneous T-cell lymphomas.
Kaplan JB; Guitart J; Giles FJ
Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2011 Nov; 86(11):928-48. PubMed ID: 21990092
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
[TBL] [Abstract][Full Text] [Related]
18. Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Duvic M
Hematology Am Soc Hematol Educ Program; 2015; 2015():529-44. PubMed ID: 26637769
[No Abstract] [Full Text] [Related]
19. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.
Moriarty B; Whittaker S
Expert Rev Hematol; 2015 Apr; 8(2):159-71. PubMed ID: 25495961
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri A; Smith JS; Larocca C
J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
[No Abstract] [Full Text] [Related]
[Next] [New Search]
